TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27414521
Drug: Oral Shilajit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Shilajit supplementation (250 mg b.i.d. for 8 weeks)
Study: 27414521
Drug: Oral Shilajit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Shilajit supplementation (250 mg b.i.d. for 8 weeks) with additional 4 weeks of supplementation with exercise
Study: 27415618
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical exercise program (PEP) including cycloergometry/kinesiotherapy plus nutritional therapy
Study: 27415618
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy (control)
Study: 27416639
Drug: FocalyxTx (treatment)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FocalyxTx (treatment)
Study: 27418646
Drug: Mogamulizumab, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab, an anti-CCR4 monoclonal antibody
Study: 27418929
Drug: Levothyroxine suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine suppression therapy (fixed dose)
Study: 27422150
Drug: Treatment after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment after 8 weeks of acute period treatment in MDD patients
Study: 27422150
Drug: Longitudinal study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Longitudinal study over 96 weeks including 8-week acute treatment and 88-week stable treatment in MDD patients
Study: 27422301
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg bid
Study: 27422301
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg bid
Study: 27422301
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg bid (expansion cohort)
Study: 27422342
Drug: IgG concentrations
Normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG concentrations >0.61-5.58μg/mL
Study: 27422342
Drug: IgG concentrations
Normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG concentrations >2.48-17.69μg/mL
Study: 27423106
Drug: Lacosamide (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (target dose: 400mg/day by the end of titration) as adjunctive treatment to levetiracetam (LEV, stable dosage of >1000mg/day)
Study: 27423106
Drug: Lacosamide (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (target dose: 400mg/day) as adjunctive treatment to levetiracetam (LEV, stable dosage of >1000mg/day)
Study: 27428731
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite (1000 µg loading dose followed by 1000 µg daily infusion until discharge, max 21 days)
Study: 27430242
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg/day) for 12 weeks
Study: 27431901
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3 measures of immune cell function (neutrophil CD88, monocyte HLA-DR, % regulatory T cells)
Study: 27432917
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg/d
Study: 27433488
Drug: Metformin Extended
Normalized name: metFORMIN Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin Extended Release (MXR) 2,000 mg daily
Study: 27435145
Drug: Real-time sensor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time sensor glucose (SG) for treatment decisions
Study: 27435882
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP) for 1 year
Study: 27436099
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg
Study: 27436285
Drug: Early stress-dose
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early stress-dose steroids
Study: 27439618
Drug: Narrative Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Exposure Therapy (NET) during a ten-week inpatient program
Study: 27439667
Drug: Patients' beliefs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' beliefs regarding medication
Study: 27440259
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g LNS-PL/d (118 kcal) containing essential fatty acids and vitamins and minerals until delivery
Study: 27440259
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe + 400 μg folic acid/d
Study: 27440658
Drug: Parent-administered physical
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered physical therapy (10 minutes twice a day for 3 weeks from 34 to 36 weeks' PMA)
Study: 27442600
Drug: Bendamustine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 40 mg/m², lenalidomide, low-dose dexamethasone
Study: 27443634
Drug: Chemotherapy (CTh)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CTh)
Study: 27443634
Drug: Localized CRC
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized CRC without chemotherapy (CTh-)
Study: 27450106
Drug: Standard-of-care therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care therapies
Study: 27450309
Drug: Histamine-2 Receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2 Receptor Antagonists (H2RAs)
Study: 27453079
Drug: Guanfacine (GUAN)
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine (GUAN) 1-3 mg/day
Study: 27453079
Drug: D-methylphenidate extended-release
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-methylphenidate extended-release (DMPH) 5-20 mg/day
Study: 27453079
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GUAN and DMPH (COMB)
Study: 27453080
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with DMPH and GUAN (COMB)
Study: 30682562
Drug: Melody valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melody valve implant
Study: 27453733
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of insulin injections
Study: 27453733
Drug: Not filling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not filling insulin prescription due to associated cost
Study: 27453734
Drug: Metabolic syndrome
Normalized name: Syndros
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metabolic syndrome (MetS) with minor allele G of ESR1 gene polymorphism (rs9340799)
Study: 27456232
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (100,000 IU) followed by 400 IU daily for 6 months
Study: 27456710
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for none
Study: 27456710
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for 1-3 months
Study: 27456710
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for 4-12 months
Study: 27456710
Drug: Low-dose-rate brachytherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose-rate brachytherapy (LDR-BT) with BED <178.0 Gy2
Study: 27456710
Drug: Low-dose-rate brachytherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose-rate brachytherapy (LDR-BT) with BED ≥178.0 Gy2
Study: 27456710
Drug: Low-dose-rate brachytherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose-rate brachytherapy (LDR-BT) with or without supplemental EBRT and ADT
Study: 27457584
Drug: Antibiotic prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescription rate
Study: 27457707
Drug: CEP-37250/KHK2804 (0.03-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-37250/KHK2804 (0.03-1.0 mg/kg) intravenously once weekly
Study: 27458003
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT)
Study: 27459380
Drug: Client-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered therapy (CCT)
Study: 27459537
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist (GLP-1-RA) exenatide for 9 weeks
Study: 27459537
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist (GLP-1-RA) exenatide
Study: 27460442
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg orally twice daily (cohort 1)
Study: 27460442
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg orally twice daily (cohort 2)
Study: 27460571
Drug: Rituximab-based chemotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-based chemotherapy (R-chemo)
Study: 27461255
Drug: Induction neoadjuvant
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction neoadjuvant chemotherapy (NACT)
Study: 27461255
Drug: Sequential chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiotherapy (CRT)
Study: 27462386
Drug: Calcipotriene/betamethasone topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene/betamethasone topical suspension (once-daily)
Study: 27463733
Drug: Rituximab (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (two infusions of 1000 mg at month 0 and 6, plus 100 mg methylprednisolone)
Study: 27465398
Drug: Overall weight,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall weight, BMI, fat mass, and subcutaneous adiposity
Study: 27465647
Drug: Ferumoxytol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol (4 mg/kg) administered prior to MRI
Study: 27466607
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum zonulin group (<46.4 ng/mL)
Study: 27467121
Drug: Sonidegib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 400 mg q.d.
Study: 27467121
Drug: Sonidegib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 600 mg q.d.
Study: 27467121
Drug: Sonidegib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 800 mg q.d.
Study: 27470087
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine A (CyA) 2 mg/kg body weight per day for 16 weeks
Study: 27471593
Drug: Lemonade (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemonade (90 g/L carbohydrates)
Study: 27471593
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (9 g/L)
Study: 27472034
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with or without radiotherapy (C/R)
Study: 27473031
Drug: Alglucosidase alfa
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Alglucosidase alfa treatment
Study: 27473350
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injection
Study: 27473726
Drug: Standard oncological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oncological therapies
Study: 27473815
Drug: Temozolomide and
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide and capecitabine-based preoperative chemoradiation therapy (CRT)
Study: 27474763
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg every 4 weeks for 4 months
Study: 27475428
Drug: TPCS2a (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPCS2a (0.25 mg/kg, escalated to 0.5, 1.0, and 1.5 mg/kg) followed by bleomycin (15,000 IU/m²) and laser illumination (652 nm, 60 J/cm²)
Study: 27475428
Drug: TPCS2a (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPCS2a (1.0 mg/kg)
Study: 27475428
Drug: TPCS2a (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPCS2a (1.5 mg/kg)
Study: 27475428
Drug: TPCS2a (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPCS2a (0.25 mg/kg)
Study: 27475674
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) dose of 36 Gy with a 9-Gy simultaneous in-field boost (SIB) to the positive margins (PM), delivered in 3 fractions.
Study: 27475674
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) dose escalation plan up to 45 Gy.
Study: 27476767
Drug: Post-treatment ICG
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment ICG retention test (ICG R)
Study: 27476790
Drug: HCT-ASCT with
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT-ASCT with rituximab 375 mg/m(2), carmustine 400 mg/m(2), thiotepa 2×5 mg/kg, and stem cell infusion
Study: 27476790
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with five courses of intravenous rituximab 375 mg/m(2) and four courses of intravenous high-dose methotrexate 8000 mg/m(2)
Study: 27476810
Drug: Piperacillin/tazobactam 4.5 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4.5 g 2-3 times daily by intermittent infusion
Study: 27476810
Drug: Piperacillin trough
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin trough level of 22.5 mg/L
Study: 27476810
Drug: Total piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total piperacillin trough levels threshold of 70 mg/L
Study: 27476810
Drug: Total piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total piperacillin target range ≥70 mg/L
Study: 27478115
Drug: 1-month triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month triple antithrombotic therapy (TAT)
Study: 27478115
Drug: >1-month triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: >1-month triple antithrombotic therapy (TAT)
Study: 27479177
Drug: NS-018 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS-018 (300 mg once daily)
Study: 27479781
Drug: Other phosphate
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other phosphate binders (concomitant therapy)
Study: 27480288
Drug: Magnetic-controlled capsule
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic-controlled capsule endoscopy (MCCE)
Study: 27480830
Drug: Leukotriene-modifying drugs
Normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene-modifying drugs
Study: 27480830
Drug: Desensitization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitization with daily aspirin therapy
Study: 27480854
Drug: Daily therapy
Normalized name: Konsyl Daily Therapy Fiber Laxative 625mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily therapy with 250 mg of AZM (n = 77)
Study: 27480854
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy with 500 mg of AZM three times weekly (n = 89)
Study: 27480854
Drug: Daily therapy
Normalized name: Konsyl Daily Therapy Fiber Laxative 625mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily therapy with 250 mg of AZM for MABC-LD (n = 55)
Study: 27483391
Drug: Pimasertib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimasertib (60 mg oral dose)
Study: 27485208
Drug: Exogenous TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous TRH administration
Study: 27485934
Drug: Facebook-based peer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facebook-based peer group intervention for mothers with weekly video-based curriculum and optional face-to-face event.
Study: 27486034
Drug: Sofosbuvir-velpatasvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg) plus GS-9857 (100 mg) once daily for 6-12 weeks
Study: 27486034
Drug: Sofosbuvir-velpatasvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg) plus GS-9857 (100 mg) once daily for 6-12 weeks plus ribavirin
Study: 27486034
Drug: Sofosbuvir-velpatasvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg) plus GS-9857 (100 mg) once daily for 12 weeks
Study: 27486033
Drug: Sofosbuvir-velpatasvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combination tablet) and GS-9857 (100 mg) once daily for 6-12 weeks
Study: 27486340
Drug: PEG 3350
Normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 3350 ASC (17 g once daily for 14 days)
Study: 27486524
Drug: ETN 25
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 25 mg + MTX
Study: 27486524
Drug: ETN 50
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 50 mg + MTX (Phase I)
Study: 27486629
Drug: Trastuzumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab with Perioperative Chemotherapy
Study: 27491288
Drug: Mobile phone
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone intervention plus treatment as usual (experimental group)
Study: 27492790
Drug: Universal decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal decolonization using intranasal mupirocin and chlorhexidine bath (2 cycles, 1 month apart)
Study: 27492881
Drug: Regional anaesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional anaesthesia (brachial plexus block [BPB] with 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine)
Study: 27492881
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia (0.5% L-bupivacaine and 1% lidocaine injected subcutaneously)
Study: 27493790
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg two times a day
Study: 27493790
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg two times a day
Study: 27494163
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine (2 doses, liquid formulation, separated by ≥4 weeks)
Study: 27494911
Drug: Decolonization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decolonization therapy with oral aminoglycosides (gentamicin and neomycin/streptomycin)
Study: 27494911
Drug: Gentamicin oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin oral therapy
Study: 27494911
Drug: Neomycin/streptomycin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin/streptomycin therapy
Study: 27495287
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) for 6 weeks
Study: 27496946
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (25-OHD <25 nmol/l)
Study: 27496946
Drug: Normal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal vitamin D levels (25-OHD >75 nmol/l)
Study: 27497862
Drug: CTX-DP (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX-DP (2 million, 5 million, 10 million, or 20 million cells by stereotactic ipsilateral putamen injection)
Study: 27499222
Drug: Pre-procedural unfractioned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-procedural unfractioned heparin
Study: 27499222
Drug: Pre-procedural 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-procedural 600mg clopidogrel loading dose
Study: 27499694
Drug: E/E' ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/E' ratio goal-directed therapy in kidney recipients with baseline diastolic dysfunction
Study: 27499979
Drug: NIR thoracoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR thoracoscope with indocyanine green (ICG) at a dosage of 0.2 mg/kg
Study: 27499979
Drug: NIR thoracoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR thoracoscope with indocyanine green (ICG) at a dosage of 0.6 mg/kg
Study: 27502708
Drug: Alisertib 50
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 50 mg PO b.i.d. d1-d7 every 21 days
Study: 27502928
Drug: Azithromycin or
Normalized name: azithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin or Doxycycline (exact dosage and duration not specified)
Study: 27502928
Drug: Self-collection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-collection of anorectal and vaginal swabs before treatment and at weeks 1, 2, 4, 6, 8, 10, and 12